ORIENT-12 Study demonstrates adding sintilimab to gemcitabine/platinum demonstrates clinical benefit over gemcitabine/platinum alone

ORIENT-12 Study demonstrates adding sintilimab to gemcitabine/platinum demonstrates clinical benefit over gemcitabine/platinum alone

Press Release
May 25, 2021
Dr. Caicun Zhou

Chris Martin, IASLC Media Relations | [email protected] | 630-670-2745

May 25, 2021 (Denver)-- Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell lung cancer, according to a study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

The standard chemotherapy for squamous NSCLC (sqNSCLC), includes platinum plus gemcitabine. sintilimab, an anti-PD-1 antibody, plus platinum/gemcitabine, has shown encouraging efficacy as first-line therapy for sqNSCLC in the phase III study ECOG 1594. Platinum/gemcitabine is another standard regimen of chemotherapy for sqNSCLC and is commonly used in Asia.

Led by Caicun Zhou, MD, Ph.D., from Shanghai Pulmonary Hospital in Shanghai, China, the researchers conducted a randomized, double-blind, phase 3 study to further compare the efficacy and safety of sintilimab with placebo, both in combination with gemcitabine/platinum.

Dr. Zhou and his co-researchers randomized patients with locally advanced or metastatic sqNSCLC and without EGFR-sensitive mutations or ALK rearrangements.  Overall, researchers screened 543 patients from 42 centers throughout China. Of those, 357 patients were randomized into the sintilimab-gemcitabine/platinum group (n=179) and the placebo-gemcitabine/platinum group (n=178).

The primary endpoint was progression-free survival (defined as the time from randomization to the first disease progression or death from any cause), as assessed by the independent radiographic review committee.

After a median follow-up period of 12.9 months, patients in the sintilimab-gemcitabine/ platinum group continued to demonstrate a meaningful improvement in progression-free survival over the placebo-gemcitabine/platinum group (HR 0.536 [95 % CI 0.422–0.681]; p<0.00001).

The incidence of treatment-emergent adverse events leading to death was 4.5 % and 6.7 % in the sintilimab-gemcitabine/platinum group and the placebo-gemcitabine/platinum group, respectively.

“In this study, the risk of disease progression or death was reduced by 37.9 % at interim analysis and by 46.4 % at updated analysis,” Dr. Zhou said.  “The results from ORIENT-12 could provide a new option for combination therapy in this patient population.”

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes nearly 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. 

About the JTO:

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

Share